StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research note published on Saturday morning. The brokerage issued a sell rating on the stock.

Separately, Piper Sandler reiterated an “overweight” rating and issued a $4.50 price objective on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Trading Down 2.8 %

Shares of NSPR stock opened at $2.40 on Friday. InspireMD has a 1 year low of $1.81 and a 1 year high of $3.48. The firm’s 50 day moving average is $2.64 and its 200-day moving average is $2.57. The firm has a market capitalization of $59.83 million, a price-to-earnings ratio of -3.24 and a beta of 0.93.

InspireMD (NYSE:NSPR) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). The firm had revenue of $1.74 million during the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. During the same quarter in the previous year, the business posted ($0.24) earnings per share. On average, equities research analysts forecast that InspireMD will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On InspireMD

A hedge fund recently raised its stake in InspireMD stock. Rosalind Advisors Inc. grew its position in InspireMD, Inc. (NYSE:NSPR) by 266.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,513,641 shares of the company’s stock after purchasing an additional 1,827,579 shares during the period. InspireMD comprises about 4.6% of Rosalind Advisors Inc.’s portfolio, making the stock its 8th largest position. Rosalind Advisors Inc. owned approximately 10.08% of InspireMD worth $6,272,000 at the end of the most recent reporting period. 44.78% of the stock is currently owned by institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.